Avalo Therapeutics (AVTX) Asset Utilization Ratio (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly Asset Utilization Ratio came in at 0.0 in Q4 2025, up 16.96% YoY from 0.0 in Q4 2024, and up 18.13% on a QoQ basis from 0.0 in Q3 2025.
Avalo Therapeutics (AVTX) Asset Utilization Ratio (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of Asset Utilization Ratio data on file, last reported at 0.0 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 16.96% year-over-year to 0.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.0 (up 16.96% YoY) and the FY2025 annual result came in at 0.0, down 91.4% from the prior year.
- Asset Utilization Ratio rose to 0.0 in Q4 2025, from 0.0 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.56 in Q2 2023 to a low of 0.0 in Q3 2025.
- A 5-year average of 0.15 and a median of 0.08 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 739.91% — and 2024, when it slumped 98.76%.
- Tracing AVTX's Asset Utilization Ratio over 5 years: stood at 0.06 in 2021, then soared by 739.91% to 0.52 in 2022, then tumbled by 85.17% to 0.08 in 2023, then slumped by 95.38% to 0.0 in 2024, then grew by 16.96% to 0.0 in 2025.
- The last three Asset Utilization Ratio figures came in at 0.0 (Q4 2025), 0.0 (Q3 2025), and 0.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.00 |
| Dec 31, 2024 | 0.00 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.02 |
| Dec 31, 2023 | 0.08 |
| Sep 30, 2023 | 0.08 |
| Jun 30, 2023 | 0.56 |
| Mar 31, 2023 | 0.50 |
| Dec 31, 2022 | 0.52 |
| Sep 30, 2022 | 0.51 |
| Jun 30, 2022 | 0.08 |
| Mar 31, 2022 | 0.09 |
| Dec 31, 2021 | 0.06 |
| Sep 30, 2021 | 0.08 |
| Jun 30, 2021 | 0.10 |
| Mar 31, 2021 | 0.08 |
| Dec 31, 2020 | 0.13 |
| Sep 30, 2020 | 0.14 |